FENNEC PHARMACEUTICALS INC. Long-Term Debt
FENNEC PHARMACEUTICALS INC. (FENC) had Long-Term Debt of $25.00 million as of 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2022-11-14
- 2022-09-30: Long-term Debt, Excluding Current Maturities $25.00M.
- 2022-06-30: Long-term Debt, Excluding Current Maturities $4.00M.
- 2022-03-31: Long-term Debt, Excluding Current Maturities $4.50M.
- 2021-12-31: Long-term Debt, Excluding Current Maturities $5.00M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2022-09-30 | $25.00M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $4.00M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $4.50M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $5.00M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |